Source: Virtual Congress 2020 – Clinical monitoring and new therapies for cystic fibrosis
Disease area: Paediatric lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. Hofland (Utrecht, Netherlands), B. Aalbers (Utrecht, Netherlands), I. Bronsveld (Utrecht, Netherlands), M. Kruijswijk (Utrecht, Netherlands), S. Schotman (Utrecht, Netherlands), H. Heijerman (Utrecht, Netherlands). Clinical response to elexacaftor/tezacaftor/ivacaftor for cystic fibrosis patients in a compassionate use setting. 363

Member's Comments

No comment yet.

Related content which might interest you: Implementation of non-medical prescribing within the clinical cystic fibrosis setting Source: International Congress 2014 – Physiotherapy and physical activity in respiratory conditions Year: 2014 The concept of cystic fibrosis pulmonary exacerbation in clinical medicine and as a trial end-point Source: Annual Congress 2008 - Exacerbations of chronic respiratory disease – state of the art Year: 2008 A new paradigm for the management of children with cystic fibrosis at home: experiences from a Dutch cystic fibrosis clinic Source: Virtual Congress 2021 – New technologies for the management of children with respiratory diseases Year: 2021 Assessment of NuvoAir platform use on clinical outcomes in adults with cystic fibrosis: a first Italian experience Source: Virtual Congress 2021 – Cystic fibrosis Year: 2021 Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry Source: Eur Respir J 2015; 46: 186-196 Year: 2015 Optimising treatment policies and improvement of care: impact on outcome in cystic fibrosis patients Source: Eur Respir J 2004; 24: Suppl. 48, 617s Year: 2004 Evaluation of adherence to medication treatment in pediatric patients with cystic fibrosis; a cross-sectional study Source: International Congress 2019 – Treatments, adherence and psychosocial aspects of cystic fibrosis Year: 2019 Standards of care for patients with cystic fibrosis Source: Eur Respir Monogr 2014; 64: 246-261 Year: 2014 The effect of transition from a paediatric to adult cystic fibrosis (CF) centre on clinical status and hospital attendance Source: International Congress 2016 – From pleura to bronchi: new insights Year: 2016 Clinical efficacy data for new diagnostic tool for the selection of the most effective antibiotics for patients with cystic fibrosis Source: Virtual Congress 2020 – Microbiology and antimicrobial strategies in cystic fibrosis Year: 2020 Real-world antifibrotic treatment persistence and clinical outcomes for patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Supportive care of patients with fibrosing interstitial lung disease: answering a great clinical need Source: Breathe, 16 (3) 200066; 10.1183/20734735.0066-2020 Year: 2020 Personalised CFTR pharmacotherapeutic response testing and therapy of cystic fibrosis Source: Eur Respir J, 51 (6) 1702457; 10.1183/13993003.02457-2017 Year: 2018 Improvement in pulmonary function after IV antibiotic treatment in cystic fibrosis patients Source: Eur Respir J 2002; 20: Suppl. 38, 342s Year: 2002 Do patients with cystic fibrosis participating in clinical trials demonstrate placebo response ? A meta-analysis. Source: International Congress 2019 – Advances in care and monitoring of cystic fibrosis Year: 2019 Challenges of providing care to adults with cystic fibrosis Source: Eur Respir Monogr 2014; 64: 286-303 Year: 2014 Diagnosis of idiopathic pulmonary fibrosis: from guidelines to clinical practice Source: Annual Congress 2009 - Clinical aspects of diffuse parenchymal lung disease Year: 2009 The treatment burden of cystic fibrosis: a day-to-day experience with treatment as someone with cystic fibrosis Source: Breathe, 17 (1) 210013; 10.1183/20734735.0013-2021 Year: 2021 The German cystic fibrosis quality assurance project: clinical features in children and adults Source: Eur Respir J 2001; 17: 1187-1194 Year: 2001